10q10k10q10k.net
LIFECORE BIOMEDICAL, INC. \DE\

LIFECORE BIOMEDICAL, INC. \DE\LFCREarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.

Q2 2026Q3 2025Q2 2025Q1 2025Q3 2024Q2 2024Q1 2024Q4 2023

Revenue

$24.5M

Gross Profit

$2.7M

Operating Profit

$-8.6M

Net Profit

$-10.8M

Gross Margin

11.1%

Operating Margin

-35.1%

Net Margin

-43.9%

YoY Growth

3.4%

EPS

$-0.35

LIFECORE BIOMEDICAL, INC. \DE\ Q1 FY2024 Financial Summary

LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $24.5M (up 3.4% YoY) for Q1 FY2024, with a net profit of $-10.8M (up 1.9% YoY) (-43.9% margin). Cost of goods sold was $21.8M, operating expenses totaled $11.3M.

Key Financial Metrics

Total Revenue$24.5M
Net Profit$-10.8M
Gross Margin11.1%
Operating Margin-35.1%
Report PeriodQ1 FY2024

Revenue Breakdown

LIFECORE BIOMEDICAL, INC. \DE\ Q1 FY2024 revenue of $24.5M breaks down across 2 segments, led by Contract Development And Manufacturing Organization at $21.5M (87.8% of total).

SegmentRevenue% of Total
Contract Development And Manufacturing Organization$21.5M87.8%
HA Manufacturing$3.0M12.2%

LIFECORE BIOMEDICAL, INC. \DE\ Annual Revenue by Year

LIFECORE BIOMEDICAL, INC. \DE\ annual revenue history includes year-by-year totals (for example, 2023 revenue was $103.3M).

YearAnnual Revenue
2023$103.3M
2022$111.3M

LIFECORE BIOMEDICAL, INC. \DE\ Quarterly Revenue & Net Profit History

LIFECORE BIOMEDICAL, INC. \DE\ results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q2 FY2026$31.1M-4.5%$-10.0M-32.1%
Q3 FY2025$35.2M-1.5%$-14.8M-42.0%
Q2 FY2025$32.6M+8.0%$-6.6M-20.2%
Q1 FY2025$24.7M+0.7%$-16.2M-65.7%
Q3 FY2024$35.7M+34.5%$15.6M43.8%
Q2 FY2024$30.1M+37.9%$14.2M47.2%
Q1 FY2024$24.5M+3.4%$-10.8M-43.9%
Q4 FY2023$31.1M+10.8%$-39.3M-126.1%

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q2 2026
Revenue$31.1M$24.5M$30.1M$35.7M$24.7M$32.6M$35.2M$31.1M
YoY Growth10.8%3.4%37.9%34.5%0.7%8.0%-1.5%-4.5%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q2 2026
Assets$253.5M$245.6M$245.8M$246.2M$246.8M$255.4M$237.7M$235.2M
Liabilities$218.5M$219.1M$203.5M$186.8M$207.3M$195.6M$190.3M$198.4M
EquityN/A$-13.6M$1.4M$17.7M$-3.9M$15.4M$2.2M$-10.5M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025Q2 2026
Operating CF$-2.3M$-8.3M$1.3M$-1.4M$-613000$-6.1M$1.2M$1.8M